• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

First-ever mycobiome atlas describes associations between cancers and fungi

October 3, 2022 Microbiome Times

An international team of scientists, co-led by researchers at the University of California San Diego School of Medicine, has created the first pan-cancer mycobiome atlas — a survey of 35 types of cancer and their […]

Editor's Choice

A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?

September 28, 2022 Kristina Campbell

Ferring Pharmaceuticals, Inc. has edged ahead in the race to bring the first microbiome-based drug to market in the United States, with its product REBYOTA receiving the thumbs up from the FDA’s Vaccines and Related […]

Editor's Choice

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

September 23, 2022 Microbiome Times

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential […]

Finance

Great learning experience to watch microbiome startups pitch

September 14, 2022 Microbiome Times

The Microbiome Signature Project arranges a Pitch Day on 27 September in Malmö, Sweden as the final event of the three-year-long project. It is a unique event to showcase startups in Medicon Valley within the […]

Pharma & Human Health

Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives

September 13, 2022 Microbiome Times

Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the registration of its phagogram as an in vitro diagnostic test (“Phagogram 1.5”) […]

Editor's Choice

Stanford researchers construct most complex, complete synthetic microbiome

September 9, 2022 Microbiome Times

Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other […]

Finance

Gensaic enters into collaboration to develop phage-derived gene therapies for CNS

September 5, 2022 Microbiome Times

Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with Ovid Therapeutics. Under the terms of the collaboration, Gensaic will exclusively develop phage-derived gene […]

Pharma & Human Health

Phage resistant Escherichia coli strains developed to reduce fermentation failure

August 25, 2022 Microbiome Times

A genome engineering-based systematic strategy for developing phage resistant Escherichia coli strains has been successfully developed through the collaborative efforts of a team led by Professor Sang Yup Lee, Professor Shi Chen, and Professor Lianrong […]

Pharma & Human Health

Phage combination therapy can precisely target IBD-related gut bacteria without harming helpful microbes

August 23, 2022 Microbiome Times

For the first time, scientists have designed a phage combination therapy that can precisely target and suppress gut bacteria associated with inflammatory bowel diseases (IBD). Presented on August 4 in the journal Cell, the work […]

Pharma & Human Health

A focus on two critical needs for developing new products in the biotics industry

August 14, 2022 Sian Lucking, PhD.

Consumers are increasingly focused on health and nutrition in their decision-making. Alongside this, interest and understanding of the importance of the gut microbiota in health and disease continues to grow. The global market for functional […]

Pharma & Human Health

New needle-free nasal vaccine shows promise for COVID-19

August 8, 2022 Microbiome Times

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mBio, an open access journal of the American Society for Microbiology. In recent […]

Posts navigation

« 1 … 27 28 29 … 86 »

QIAGEN’S NEW HIGH-THROUGHPUT BENCHTOP AUTOMATION SYSTEM

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter